The NCPE believe that when compared to alternative biological agents aflibercept may be considered cost saving.

The NCPE does not recommend reimbursement of vismodegib.

The NCPE do not recommend reimbursement of dapagliflozin.

The NCPE do not recommend reimbursement of Subcutaneous Abatacept (Orencia®) at the submitted price.

Pregabalin is currently reimbursed. The NCPE consider that it may be cost effective under certain assumptions.

The NCPE believes that pertuzumab in combination with trastuzumab and docetaxel is not a cost-effective treatment for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy.

The NCPE do not consider Crizotinib (Xalkori) a cost-effective treatment for adult patients with previously treated ALK positive advanced non small cell lung cancer (NSCLC).

The NCPE do not consider ruxolitinib to be a cost effective treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

The NCPE conclude that apixaban can be considered cost effective for the prevention of stroke and systemic embolism in people with non valvular atrial fibrillation.

The NCPE believe that Omacor® is not a cost-effective adjuvant treatment for patients post-myocardial infarction in the Irish Healthcare Setting. The cost effectiveness of Omacor® for treatment of endogenous hypertriglyceridaemia as a supplement to diet has not been demonstrated.